Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413660 · ClinicalTrials.gov registry record · Phase 2
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
A Phase 2 study of Arthritis, Rheumatoid, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 509
- Enrollment target
- 20
- Study locations
NCT00413660: Completed Phase 2 study of Arthritis, Rheumatoid, sponsored by Pfizer.
NCT00413660 is a Phase 2 study of Arthritis, Rheumatoid that has completed, run by Pfizer. The registered enrollment target is 509 participants, below the 622-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00413660, a Phase 2 study of Arthritis, Rheumatoid, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 509 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.
Primary Outcome
ACR20 response: \>= 20% improvement in tender joints count (TJC); \>= 20% improvement in swollen joints count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Conditions Studied
Interventions
- DRUG CP-690,550
Study Locations (20)
Florida
- Pfizer Investigational Site - DeBary
- Pfizer Investigational Site - Lake Mary
- Pfizer Investigational Site - Ocala
- Pfizer Investigational Site - Orlando
- Pfizer Investigational Site - Tampa
- Pfizer Investigational Site - Zephyrhills
Illinois
- Pfizer Investigational Site - Rockford
- Pfizer Investigational Site - Rockford
New York
- Pfizer Investigational Site - Albany
- Pfizer Investigational Site - Binghamton
North Carolina
- Pfizer Investigational Site - Charlotte
- Pfizer Investigational Site - Raleigh
Arizona
- Pfizer Investigational Site - Gilbert
Arkansas
- Pfizer Investigational Site - Hot Springs
California
- Pfizer Investigational Site - Upland
Colorado
- Pfizer Investigational Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
What the finished NCT00413660 record still lists
NCT00413660 is an interventional study that assigns participants to a tested intervention. The registered 509 participants enrollment target is mid-sized for trials with a published cap, below the 622-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 1 intervention - of which CP-690,550 is the first listed.
NCT00413660 names 20 study sites across 12 states, led by Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00413660 about?
NCT00413660 is a clinical study titled "Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis". The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.
What is the current status of trial NCT00413660?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 509 participants. The study started on 2007-01. Estimated completion is 2008-08.
What conditions does trial NCT00413660 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT00413660?
The interventions under investigation include: CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT00413660?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00413660 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00413660's enrollment target sits among peer trials
509 9th of 27 higher than 19 of 27 other Arthritis, Rheumatoid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Rheumatoid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
RECRUITING · Phase 2
-
A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
COMPLETED · Phase 2
-
Low Dose Naltrexone for Chronic Pain From Arthritis
COMPLETED · Phase 2
-
Chronic Pain in Rheumatoid Arthritis
RECRUITING
-
R-2487 in Patients With Rheumatoid Arthritis
RECRUITING · Phase 1
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia